Numoda new products for CT unblinding
In a further expansion of its offerings for preventing clinical trial failure, Philadelphia-based Numoda Corporation has developed its capacity to safely provide blinded reports at any interval during a trial, without sacrificing 'p-value'.
In a further expansion of its offerings for preventing clinical trial failure, Philadelphia-based Numoda Corporation has developed its capacity to safely provide blinded reports at any interval during a trial, without sacrificing 'p-value'.
This is particularly significant in trials where enrollment is difficult or speed is imperative, whether in the race for the cure or the race against the competition.
Numoda reporting products reveal success distribution among the study arms, by percentage. The chief medical officer or chief scientific officer can know if the percentage is not consistent, or if there is no single improvement. 'Whereas an interim analysis requires a statistical penalty, Numoda's products enable analysis with no statistical penalty, and the analysis can be made earlier than previously possible. We are achieving things that no clinical development services company has been able to accomplish,' said Ann Boris, senior vice president of Clinical Operations. As one CMO told Boris: 'With these reports we can see if we are in trouble much sooner, before we spend the clinical development money or lose all that time.'